Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor–Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance)

2020; Lippincott Williams & Wilkins; Volume: 38; Issue: 12 Linguagem: Inglês

10.1200/jco.19.00510

ISSN

1527-7755

Autores

E. Shelley Hwang, Terry Hyslop, Laura H. Hendrix, Stephanie Q. Duong, Isabelle Bedrosian, Elissa R. Price, Abigail S. Caudle, Tina J. Hieken, Joseph M. Guenther, Clifford A. Hudis, Eric P. Winer, Alan P. Lyss, Diana Dickson-Witmer, Richard Hoefer, David W. Ollila, Timothy Hardman, Jeffrey R. Marks, Yunn-Yi Chen, Gregor Krings, Laura J. Esserman, Nola M. Hylton,

Tópico(s)

Breast Lesions and Carcinomas

Resumo

Primary endocrine therapy for ductal carcinoma in situ (DCIS) as a potential alternative to surgery has been understudied. This trial explored the feasibility of a short-term course of letrozole and sought to determine whether treatment results in measurable radiographic and biologic changes in estrogen receptor (ER)-positive DCIS.

Referência(s)